Estée Lauder
No proof required
Up to $5,000
Claims opening soon
O
Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc.
Canadians prescribed the drug Rexulti who developed compulsive behaviors may claim a share of a $4.75 million settlement.
ClosedQuebec onlyClaim status: Closed on August 27, 2026Payout: Up to $102,000No longer claimable
About this settlement
Class action for Canadians prescribed Rexulti who developed compulsive or impulse-control disorders.
A national class action in Canada against Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. resulted in a $4.75 million settlement approved by Quebec Superior Court. The lawsuit concerns the antipsychotic drug Rexulti, prescribed since February 2017, and its alleged link to compulsive behaviors and impulse-control disorders such as gambling, shopping, or binge-eating. Eligible claimants may receive compensation based on the severity of their condition. The deadline to file claims is August 27, 2026.
Who qualifies
- Canadians prescribed Rexulti since February 2017.
- Those who developed compulsive behaviors or impulse-control disorders such as gambling, shopping, or binge-eating after taking Rexulti.
- Eligibility confirmed through the official claim process.
Up to $102,000
Claim status: Closed on August 27, 2026
Silk and Great Value
Proof required
Up to $300,000
31 days left
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
681 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon